New Releases from NCBI BookshelfFutibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement.Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement.By admin / January 14, 2025 Post Content